Omidenepag Isopropyl
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Omidenepag Isopropyl: From Ocular Hypertension and Glaucoma to Pancreatitis
One-Sentence Summary
Omidenepag isopropyl is an ophthalmic drug originally used to treat ocular hypertension and glaucoma. The TxGNN model predicts it may be effective for pancreatitis, but there are currently 0 clinical trials and 0 publications supporting this direction, so the prediction rests on the computational model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Ocular hypertension, glaucoma (from the knowledge graph; the Singapore licence records contain no indication text) |
| Predicted New Indication | Pancreatitis |
| TxGNN Prediction Score | 99.76% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled data. Omidenepag isopropyl is understood to be a selective prostanoid EP2 receptor agonist applied to the eye. Its efficacy in lowering intraocular pressure is the basis of its use in ocular hypertension and glaucoma.
No direct mechanistic link between EP2 receptor agonism and pancreatitis is established in the data compiled for this report. The high TxGNN score (99.76%) is a knowledge-graph prediction only, and it likely reflects shared network neighbours rather than biological evidence. In addition, the eye-drop form gives minimal systemic exposure, which makes a pancreatic effect even less plausible without a different formulation or route.
Other top-ranked predictions (for example hyperphosphatemia, esophageal varices, blepharospasm and familial visceral myopathy) also have scores above 99% with no supporting trials or publications. This suggests the score alone does not discriminate well among them.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16150P | EYBELIS OPHTHALMIC SOLUTION 0.002% | Sterile solution | Not stated in the licence record |
| SIN16951P | EYBELIS-S OPHTHALMIC SOLUTION 0.002% w/v | Sterile solution | Not stated in the licence record |
Both licences are valid single-ingredient products manufactured by Santen Pharmaceutical Co., Ltd. (Shiga Plant and Noto Plant respectively).
Safety Considerations
Please refer to the package insert for safety information. No interaction records were found for this drug, and no contraindicated diseases were identified in the knowledge graph.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical trials or publications behind it (Evidence Level L5), and no plausible mechanistic link between EP2 agonism and pancreatitis. The ocular-only formulation also limits systemic exposure. The remaining top predictions are similarly unsupported.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA website, which are currently missing and block safety screening
- Detailed mechanism of action data from DrugBank
- Preclinical or mechanistic evidence linking EP2 signalling to pancreatic inflammation
- An assessment of whether a non-ocular formulation or route would be needed to reach relevant tissue
- A literature and trial search specific to pancreatitis, and a comparison with the other predicted indications to find any with real supporting evidence
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.